OncoMatch/Clinical Trials/NCT06712745
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
Is NCT06712745 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies non-drug interventions for cancer, lung.
The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
Check if I qualifyExtracted eligibility criteria
Performance status
ZUBROD/ECOG 0–2
Prior therapy
Cannot have received: radiation therapy
Exception: to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Cannot have received: anti-VEGF therapy
Exception: within 1 year
Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify